Global Precision Oncology Diagnostics Market Size Likely to Grow at a CAGR of 7.95% By 2035

Market Size and Growth

The precision oncology diagnostics market size was valued at USD 19.53 billion in 2026 and is anticipated to reach USD 39.1 billion by 2035 with a compound annual growth rate of 7.95% from 2026 to 2035.

Global Precision Oncology Diagnostics Market Revenue and Trends

The Precision Oncology Diagnostics market is based on the use of modern molecular diagnostic technologies such as next-generation sequencing (NGS), liquid biopsy, companion diagnostics, genomic profiling, biomarker testing, AI (artificial intelligence)-based diagnostics, digital pathology and multi-omics analysis to detect and select treatment and manage therapies to detect and prevent cancer.

These advanced technologies are revolutionizing healthcare across hospitals, cancer treatment centers, diagnostic labs, pharma and biotechnology companies, and research institutions and are facilitating personalized cancer diagnosis and therapy choice, discovery of cancer biomarkers, assessment of minimum residual disease (MRD), and guided decisions that support precision medicine. There is a strong demand for precision oncology diagnostics with the growing prevalence of cancer across the globe, increasing use of personalized medicine and genomic testing, demand for targeted drugs and high investment in research & development of precision oncology.

What are the Factors That Have a Significant Contribution to the Growth of the global Precision oncology diagnostics market?

Increasing focus towards personalized treatment approaches for cancer has significantly boosted the adoption of precision oncology diagnostics across the globe. Healthcare providers are increasingly opting for genomic profiling, companion diagnostics, liquid biopsy and molecular biomarker testing to detect the actionable mutations, predicting the response to therapies and selecting targeted treatments for oncology patients.

The rise in the incidence of oncology cases, the growing availability of cutting-edge sequencing technologies and the increased requirement for precise disease characterization have motivated hospitals, cancer centers and diagnostic laboratories to embrace precision diagnostic solutions. Increasing partnerships among pharmaceutical companies, diagnostic manufacturers, and research institutes for developing biomarker-guided therapies and companion diagnostics are also creating a favorable ecosystem for market growth.

Rapid advances in areas such as next-generation sequencing (NGS), artificial intelligence (AI), digital pathology, multi-omics, and liquid biopsy have been driving substantial transformation in precision oncology diagnostics workflows. Modern precision oncology diagnostics platforms are used to carry out genomic profiling, facilitate early diagnosis of cancer, track the ongoing treatments in real-time and detect mechanisms of resistance via the use of sophisticated molecular analyses. Growing investment in cancer genomics, targeted therapies and biomarker research from healthcare providers, biotechnology firms, pharmaceutical companies and research organizations will drive significant opportunities for the precision oncology diagnostics market in the coming years.

Opportunities Impact Analysis

Challenges Impact Analysis

Segment Insight

By Product

Consumables & Reagents represent the largest product segment, thanks to recurrent sales of sequencing kits, PCR reagents, antibodies, probes, sample preparation kits, and various other assay consumables, all used for molecular oncology tests. The increased application of companion diagnostics, next-generation sequencing (NGS), liquid biopsy, and comprehensive genomic profiling helps keep up the demand. While instruments and services products are needed to help out with any laboratory-specific operations and tests performed.

By Technology

Next-Generation Sequencing (NGS) leads the pack within the technology segment since it is necessary for performing comprehensive genomic profiling and it can test for numerous targetable mutations at one point to provide accurate and personalized cancer treatment. Continued improvements are being made to NGS sequencing accuracy, throughput, and even cost efficiency, thus fueling further implementation of NGS sequencing throughout hospitals, clinical laboratories, pharmaceutical companies, and even in cancer research institutions.

By Biomarker Type

Genetic mutations hold the majority within the biomarker type segment since they are key to identifying clinically actionable mutations and consequently determining which targets will provide targeted treatment for a particular case of cancer, paving the way for personalized oncology treatment. Mutation tests forEGFR,KRAS,BRAF,ALK,ROS1,BRCA1/2,PIK3CA, and others are widely used across all of oncology diagnoses and as a complementary application for companion diagnostics, helping drive the overall market forward.

By Sample Type

Tissue biopsy dominates this segment thanks to the wide acceptance and implementation of tissue samples as the gold standard for cancer diagnosis, the assessment of histological data, molecular biomarker detection, and comprehensive genomic profiling. While tissue specimens offer the best results when it comes to defining tumors for targeted therapies, liquid biopsy is a convenient addition for cancer progression monitoring and as a non-invasive method for certain types of testing.

Regional Insights

North America is by far the largest market for Precision Oncology Diagnostics due to its high level of adoption for genomic sequencing, the well-established infrastructure in molecular diagnostics, the many precision medicine initiatives that exist, good reimbursement, and the presence of numerous top-notch pharmaceutical, diagnostic, and biotechnology companies. Significant continued investment in genomic research for cancer and biomarkers, along with companion diagnostics, solidifies North America’s position.

Asia Pacific is projected to grow the most over the forecast period. This is attributed to the increase in the prevalence of cancer, broader use of precision medicine programs, increased investment in genomic sequencing infrastructure, and faster advancement of healthcare systems in these regions. China, Japan, India, South Korea, Singapore, and Australia are all adopting these tests, such as Liquid Biopsy and AI-enhanced oncology.

Report Scope

Recent Developments

• April 2025: Roche Diagnostics expanded its precision oncology offering with new molecular diagnostics and digital pathology innovations that unite AI-powered image analysis with companion diagnostic tests. The advancements are designed to facilitate rapid identification of biomarkers, the selection of targeted therapies, and better clinical decision-making in oncology.

List of the prominent players in the Precision Oncology Diagnostics Market:

• F. Hoffmann-La Roche Ltd.

• Illumina Inc.

• Thermo Fisher Scientific Inc.

• QIAGEN N.V.

• Agilent Technologies Inc.

• Danaher Corporation

• Abbott Laboratories

• Guardant Health Inc.

• Exact Sciences Corporation

• Natera Inc.

• Myriad Genetics Inc.

• Foundation Medicine Inc. (Roche)

• Bio-Rad Laboratories Inc.

• NeoGenomics Laboratories Inc.

• Siemens Healthineers AG.

• Others

The Precision Oncology Diagnostics Market is segmented as follows:

By Product

• Instruments

• Consumables & Reagents

• Software & Analytics

• Services

By Technology

• Next-Generation Sequencing (NGS)

• Polymerase Chain Reaction (PCR)

• Digital PCR (dPCR)

• Immunohistochemistry (IHC)

• Fluorescence In Situ Hybridization (FISH)

• In Situ Hybridization (ISH)

• Microarrays

• Liquid Biopsy Technologies

• Mass Spectrometry

• AI-enabled Molecular Diagnostics

By Biomarker Type

• Genetic Mutations

• Gene Expression Biomarkers

• Protein Biomarkers

• Epigenetic Biomarkers

• Circulating Tumor DNA (ctDNA)

• Circulating Tumor Cells (CTCs)

• Tumor Mutational Burden (TMB)

• Microsatellite Instability (MSI)

By Sample Type

• Tissue Biopsy

• Blood (Liquid Biopsy)

• Bone Marrow

• Saliva

• Urine

• Other

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America